Investors and Media

Investor Relations

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Cancer is one of the most difficult diseases to treat. It is constantly changing, requiring new and more sophisticated therapies.

Replimune is pioneering a new generation of cancer treatments called oncolytic immunotherapies. These cleverly designed therapeutics combine multiple mechanisms of action, enhancing the ability of viruses to replicate in and kill cancer cells, generating a powerful patient-specific, systemic immune response.

Oncolytic immunotherapy enhances the effectiveness of immune checkpoint blockade and is expected to become the second cornerstone of immuno-oncology (IO) approaches, moving beyond incremental improvements in cancer treatment to help more patients overcome their disease.

Press Releases
Jun 13, 2024
- Led by a life-sciences focused institutional investor, with participation from Redmile Group , RTW Investments, Boxer Capital and other institutional investors - - Financing follows strong primary analysis data from the RP1 IGNYTE clinical trial in anti-PD1 failed melanoma; BLA filing expected in